News Releases

Date	Title and Summary	View
Oct 14, 2021	Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
Oct 13, 2021	New Subgroup Analysis of the Phase 3 OPTIMUM Study Demonstrates the Benefits of PONVORYTM (ponesimod) Over teriflunomide in Early Disease Multiple Sclerosis
Oct 13, 2021	Johnson & Johnson to Host Business Review Highlighting Pharmaceuticals
Oct 12, 2021	Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson To Retire, Effective December 31, 2021
Oct 12, 2021	Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference
Oct 11, 2021	Johnson & Johnson to Participate in the Credit Suisse 30th Annual Healthcare Conference
Oct 08, 2021	Janssen Submits Application Seeking U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
Oct 06, 2021	Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature
Oct 05, 2021	Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
Oct 04, 2021	New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA® (ustekinumab) in Older Patients Across Approved Indications